Proceeds enable expansion and scale of ElevateBio’s cell and gene technology platforms, end-to-end capabilities, and therapeutic pipeline to serve an increasing number of biopharmaceutical partners and drive revenue growth
ElevateBio has added more than 15 new biopharma partners across its ecosystem over the past year, including strategic gene editing collaborations with Moderna and Novo Nordisk
